Company intelligence / Profile preview
DAAN Biotherapeutics
- Ownership
- Private
- Development stage
- Other
Overview
DAAN Biotherapeutics is a Korean oncology biotech developing TCR- and T-cell–engager–based therapies, NK cell therapies, antibodies (including ADC-enabling antibodies), and small molecule inhibitors for solid tumors, particularly EGFR‑mutant lung cancer; its lead NK/TCR cell therapy and antibody programs are in preclinical development with plans for global clinical trials around 2026.
- Therapeutic areas
- Oncology
- Modalities
- Cell therapyTCR-T cell therapyNK cell therapyMonoclonal antibodyBispecific monoclonal antibodyAntibody-drug conjugateSmall molecule
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on DAAN Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DAAN Biotherapeutics.